| abstract |
Use of an oral pharmaceutical composition to reduce the intestinal passage effect on the active principle contained in, the said composition being in the form of a system which is self-microemulsifying on contact with an aqueous phase, comprising: n a therapeutically effective amount of the said active principle; n a lipophilic phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with at least one fatty acid chosen from the group comprising C 8 -C 18 fatty acids; n a surfactant phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with caprylic acid (C 8 ) and capric acid (C 10 ); n a co-surfactant phase comprising at least one ester of a polyvalent alcohol with at least one fatty acid chosen from the group comprising caprylic esters of propylene glycol, lauric esters of propylene glycol and oleic esters of polyglycerol, n the ratio TA/CoTA being between 0.2 and 6. |